ÂÜÀòÂÒÂ×

Richard Mohs, Ph.D., has served as the Vice President of Clinical Development since December 2015. Dr. Mohs offers more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacestat.

Dr. Mohs now leads the AgeneBio clinical trial on the efficacy of AGB101 in patients with MCI due to AD. He is also P.I. on a NIIH award supporting the Phase 2b trial to include biomarker development using [18F]MK-6420 for tau PET imaging. Dr. Mohs served as Eli Lilly’s Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories, where he led a clinical development team targeting Alzheimer’s disease or other neurodegenerative diseases, pain, depression, or schizophrenia. Previously, he was a Professor in the Department of Psychiatry with the Mount Sinai School of Medicine and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. During this time, he was instrumental in designing clinical trials that led to the approval in the US and other countries of cholinergic drug treatments for Alzheimer’s disease. He has served as an advisor to many neuroscience research programs at universities in the United States and to several foundations supporting neuroscience research including the John D. and Catherine T. MacArthur Foundation, the Charles A. Dana Foundation and has recently been appointed to the Board of Governors for the Alzheimer’s Drug Discovery Foundation. Dr. Mohs received his Ph.D. in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School.